UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 13(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

Exscientia Business and Financial Update for the Full Year 2023 OXFORD, U.K. – Exscientia plc (Nasdaq: EXAI) Recent advancements in the Company's pipeline, collaborations and operations, as well as financial results for the fourth quarter and full year 2023, are summarised below. Exscientia will host a conference call Thursday, March 21 at 12:30 p.m. GMT / 8:30 a.m. EDT. "In 2023, we significantly expanded our technological capabilities with the opening of our automation facility, concentrated our internal ...

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) will report financial results for the fourth quarter and full year ended December 31, 2023, on Thursday, March 21, 2024, before the open of U.S. markets. The Company will host a conference call and webcast at 12:30 p.m. GMT / 8:30 a.m. EDT to provide a business update and review financial results. A webcast of the live call can be accessed by visiting the “Investors and Media” section of the Company’s website at investors.exscientia.ai. Altern ...

Healthcare stocks have started the year off very strongly, propelled by excitement about weight loss drugs and investments by Nvidia (NASDAQ:NVDA). The sector is also getting a lift from the U.S. Federal Reserve’s decision to stop raising rates and its suggestions that it will cut rates later this year. Lower rates make it much easier for drug makers to obtain funds to finance the development of pharmaceuticals. Meanwhile, many pharmaceutical firms have rather low valuations because they dropped sharply in ...

Nasdaq-listed Exscientia shares crashed by more than a fifth as the Oxford-based biotech fired its founder and chief executive over "inappropriate relationships" with two employees. In a statement, the AI-focused drug developer said that Andrew Hopkins's behaviour was inconsistent with “the company’s standards and values”. Hopkins has been removed from his role on the board effective immediately, with a special committee established and an outside counsel appointed to look into his behaviour. Chairman David ...

OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced the initiation of EXCYTE-2, an observational clinical study in acute myeloid leukaemia (AML) to investigate the relationship between ex vivo drug response (EVDR) measured in primary blood or bone marrow samples using the company’s deep learning, single-cell precision medicine platform and actual patient clinical response. The EXCYTE-2 study will collect blood and bone marrow samples from first-line patients with AML, with an ...

Operator Unidentified Analyst   Yes. Steve, good to speak to you. Actually, Charlotte Dean will be presenting at PEG next Wednesday on the results weÂ've already generated on our proof-of-concept work. WeÂ're very excited actually by that data, which actually explores multiple different methodologies. So I recommend actually look out for Charlotte presentation next week. You described looking at how the partnership business can be more nimble in the future. Perhaps it suggests that the arrangements that y ...

I'll speak in a moment about our core capability to adapt and rapidly integrate technological advances into our broad platform. Technology is at the center of our strategy to change the way drugs are invented and developed. To maintain nimble product development in our technology platform, we have promoted three industry leaders to our executive committee. Professor Charlotte Deane is our new Chief AI Officer. Dr. John Overington is our new Chief Data Officer; and Eileen Jennings-Brown, our Chief informatio ...

Call Start: 08:30 January 1, 0000 9:11 AM ET Exscientia plc (NASDAQ:EXAI) Q1 2023 Earnings Conference Call May 24, 2023 08:30 ET Company Participants Sara Sherman - Vice President of Investor Relations Andrew Hopkins - Chief Executive Officer Dave Hallett - Chief Scientific Officer Ben Taylor - Chief Financial Officer & Chief Strategy Officer Garry Pairaudeau - Chief Technology Officer Mike Krams - Chief Quantitative Medicine Officer Conference Call Participants Alec Stranahan - Bank of America Peter Lawson ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ FORM 6-K ___________________________________ REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Section 13a-16 OR 15d-16 of the Securities Exchange Act of 1934 for the Month of May 2023 Commission File Number: 001-40850 ___________________________________ Exscientia plc (Translation of registrant's name into English) ___________________________________ The Schrödinger Building Oxford Science Park Oxford OX4 ...